The Latest Breaking News from Intellia Therapeutics

Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity

Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.

Barchart · Sep 29

Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying

Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.

Barchart · May 5

Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares?

Barchart · Apr 27

Intellia Therapeutics Shares Are Ripping Higher: Here's Why

Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones.

Benzinga · Sep 18, 2025

Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?

Cathie Wood recently acquired shares of the biotech company. Should you do the same?

Barchart · Aug 21, 2025

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

MarketBeat · Jul 15, 2025

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

Barchart · Feb 19, 2025

This Cathie Wood Stock Can Soar 221%, Says Wall Street

Promising clinical trial results have analysts optimistic about the company’s future.

Barchart · Aug 7, 2024

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Barchart · Jun 3, 2024

'This is the future': ACT trials gene-editing to treat heart patient

The technology is literally 'cutting' edge.

The Canberra Times · Jun 2, 2024